Published in Nat Nanotechnol on July 29, 2007
Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater (2009) 11.95
Design considerations for tumour-targeted nanoparticles. Nat Nanotechnol (2009) 4.06
Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv Drug Deliv Rev (2008) 3.18
Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm (2008) 2.94
Toxicity and cellular uptake of gold nanoparticles: what we have learned so far? J Nanopart Res (2010) 2.70
Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev (2009) 2.57
Tissue- and organ-selective biodistribution of NIR fluorescent quantum dots. Nano Lett (2009) 2.37
Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev (2012) 2.11
Perturbational profiling of nanomaterial biologic activity. Proc Natl Acad Sci U S A (2008) 2.04
Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. Nat Nanotechnol (2013) 1.92
Nanoparticle-induced surface reconstruction of phospholipid membranes. Proc Natl Acad Sci U S A (2008) 1.90
The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine (2012) 1.83
Effects of nanomaterial physicochemical properties on in vivo toxicity. Adv Drug Deliv Rev (2009) 1.80
Nanoparticles and the immune system. Endocrinology (2009) 1.79
Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov (2011) 1.78
Evaluation of nanoparticle immunotoxicity. Nat Nanotechnol (2009) 1.70
In vitro assessments of nanomaterial toxicity. Adv Drug Deliv Rev (2009) 1.67
Noble metal nanoparticles applications in cancer. J Drug Deliv (2011) 1.66
Biopersistence and potential adverse health impacts of fibrous nanomaterials: what have we learned from asbestos? Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 1.64
Nanotechnology, nanotoxicology, and neuroscience. Prog Neurobiol (2008) 1.59
Progress in microRNA delivery. J Control Release (2013) 1.58
Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future. Chem Soc Rev (2012) 1.55
Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One (2011) 1.53
Mechanism for the endocytosis of spherical nucleic acid nanoparticle conjugates. Proc Natl Acad Sci U S A (2013) 1.53
Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine (Lond) (2010) 1.51
Nanoparticle-detained toxins for safe and effective vaccination. Nat Nanotechnol (2013) 1.50
Gold nanoparticles: a revival in precious metal administration to patients. Nano Lett (2011) 1.47
Mechanism of hard-nanomaterial clearance by the liver. Nat Mater (2016) 1.44
Biodistribution of TNF-alpha-coated gold nanoparticles in an in vivo model system. Nanomedicine (Lond) (2009) 1.44
Passive tumor targeting of renal-clearable luminescent gold nanoparticles: long tumor retention and fast normal tissue clearance. J Am Chem Soc (2013) 1.43
Top-down particle fabrication: control of size and shape for diagnostic imaging and drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 1.40
Regulating immune response using polyvalent nucleic acid-gold nanoparticle conjugates. Mol Pharm (2009) 1.40
Supramolecular nanostructures formed by anticancer drug assembly. J Am Chem Soc (2013) 1.40
Functionalized carbon nanotubes for potential medicinal applications. Drug Discov Today (2010) 1.39
Tissue-specific gene delivery via nanoparticle coating. Biomaterials (2009) 1.34
Endocytosis and exocytosis of nanoparticles in mammalian cells. Int J Nanomedicine (2014) 1.34
Mechanism of cellular uptake of highly fluorescent conjugated polymer nanoparticles. Biomacromolecules (2010) 1.33
Gold nanoparticles: opportunities and challenges in nanomedicine. Expert Opin Drug Deliv (2010) 1.32
Cadmium-containing nanoparticles: perspectives on pharmacology and toxicology of quantum dots. Toxicol Appl Pharmacol (2009) 1.31
Surface charge-mediated rapid hepatobiliary excretion of mesoporous silica nanoparticles. Biomaterials (2010) 1.29
Challenges in development of nanoparticle-based therapeutics. AAPS J (2012) 1.28
Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin Cancer Res (2012) 1.24
Nanoparticles for biomedical imaging. Expert Opin Drug Deliv (2009) 1.23
PEGylation and zwitterionization: pros and cons in the renal clearance and tumor targeting of near-IR-emitting gold nanoparticles. Angew Chem Int Ed Engl (2013) 1.23
Preclinical evaluation of Raman nanoparticle biodistribution for their potential use in clinical endoscopy imaging. Small (2011) 1.21
Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. Nano Lett (2011) 1.21
Method for analysis of nanoparticle hemolytic properties in vitro. Nano Lett (2008) 1.20
Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. Biomaterials (2011) 1.20
Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces. J Biol Chem (2010) 1.20
Multifunctional Quantum Dots for Personalized Medicine. Nano Today (2009) 1.19
Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. Biomaterials (2009) 1.19
A Raman-based endoscopic strategy for multiplexed molecular imaging. Proc Natl Acad Sci U S A (2013) 1.18
Intradermal air pouch leukocytosis as an in vivo test for nanoparticles. Int J Nanomedicine (2013) 1.16
Rapid green synthesis of silver nanoparticles from Chrysanthemum indicum L and its antibacterial and cytotoxic effects: an in vitro study. Int J Nanomedicine (2014) 1.16
Differential stability of lead sulfide nanoparticles influences biological responses in embryonic zebrafish. Arch Toxicol (2010) 1.16
A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease. ACS Nano (2014) 1.16
Degradable polyester scaffolds with controlled surface chemistry combining minimal protein adsorption with specific bioactivation. Nat Mater (2011) 1.15
Gold nanoparticles in biology and medicine: recent advances and prospects. Acta Naturae (2011) 1.12
Inorganic nanoparticles in cancer therapy. Pharm Res (2010) 1.11
Multifunctional nanoparticles for brain tumor imaging and therapy. Adv Drug Deliv Rev (2013) 1.07
Quantum dots for cancer research: current status, remaining issues, and future perspectives. Cancer Biol Med (2012) 1.07
Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res (2013) 1.06
Protein corona composition of superparamagnetic iron oxide nanoparticles with various physico-chemical properties and coatings. Sci Rep (2014) 1.06
Targeting gold nanocages to cancer cells for photothermal destruction and drug delivery. Expert Opin Drug Deliv (2010) 1.06
Bio-inspired detoxification using 3D-printed hydrogel nanocomposites. Nat Commun (2014) 1.06
Evaluation of iron oxide nanoparticle biocompatibility. Int J Nanomedicine (2011) 1.06
Accelerating the Translation of Nanomaterials in Biomedicine. ACS Nano (2015) 1.05
Nanotechnology-novel therapeutics for CNS disorders. Nat Rev Neurol (2012) 1.05
Cytokines as biomarkers of nanoparticle immunotoxicity. Chem Soc Rev (2013) 1.05
Experimental considerations on the cytotoxicity of nanoparticles. Nanomedicine (Lond) (2011) 1.05
Management of nanomaterials safety in research environment. Part Fibre Toxicol (2010) 1.04
NLRP3 inflammasome activation induced by engineered nanomaterials. Small (2012) 1.03
Preparation of cells for assessing ultrastructural localization of nanoparticles with transmission electron microscopy. Nat Protoc (2010) 1.02
Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects. Part Fibre Toxicol (2011) 1.02
PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses. Int J Nanomedicine (2012) 1.01
Physicochemical properties determine nanomaterial cellular uptake, transport, and fate. Acc Chem Res (2012) 1.00
Unambiguous observation of shape effects on cellular fate of nanoparticles. Sci Rep (2014) 1.00
Engineered biocompatible nanoparticles for in vivo imaging applications. J Am Chem Soc (2010) 1.00
Polymeric Nanostructures for Imaging and Therapy. Chem Rev (2015) 0.99
Analysis of the murine immune response to pulmonary delivery of precisely fabricated nano- and microscale particles. PLoS One (2013) 0.98
Calculation of adsorption free energy for solute-surface interactions using biased replica-exchange molecular dynamics. Biointerphases (2008) 0.97
Nanotargeted radionuclides for cancer nuclear imaging and internal radiotherapy. J Biomed Biotechnol (2010) 0.97
Mechanism of cellular uptake of genotoxic silica nanoparticles. Part Fibre Toxicol (2012) 0.96
Nanotherapy for Cancer: Targeting and Multifunctionality in the Future of Cancer Therapies. ACS Biomater Sci Eng (2015) 0.95
Engineered nanomaterial uptake and tissue distribution: from cell to organism. Int J Nanomedicine (2013) 0.95
Identifying new therapeutic targets via modulation of protein corona formation by engineered nanoparticles. PLoS One (2012) 0.95
Magnetic targeting of nanoparticles across the intact blood-brain barrier. J Control Release (2012) 0.95
Nanoscale artificial antigen presenting cells for T cell immunotherapy. Nanomedicine (2013) 0.95
The dendritic cell response to classic, emerging, and homeostatic danger signals. Implications for autoimmunity. Front Immunol (2013) 0.94
Polymeric nanoparticles: potent vectors for vaccine delivery targeting cancer and infectious diseases. Hum Vaccin Immunother (2013) 0.94
Nanomolecular targeting of dendritic cells for ovarian cancer therapy. Future Oncol (2009) 0.94
Doxorubicin-conjugated quantum dots to target alveolar macrophages and inflammation. Nanomedicine (2010) 0.93
Steering carbon nanotubes to scavenger receptor recognition by nanotube surface chemistry modification partially alleviates NFκB activation and reduces its immunotoxicity. ACS Nano (2011) 0.93
Shear-thinning nanocomposite hydrogels for the treatment of hemorrhage. ACS Nano (2014) 0.93
Inflammatory response to intravitreal injection of gold nanorods. Br J Ophthalmol (2012) 0.91
Surface charges and shell crosslinks each play significant roles in mediating degradation, biofouling, cytotoxicity and immunotoxicity for polyphosphoester-based nanoparticles. Sci Rep (2013) 0.91
Tunable nanostructured coating for the capture and selective release of viable circulating tumor cells. Adv Mater (2015) 0.91
Recognition of dextran-superparamagnetic iron oxide nanoparticle conjugates (Feridex) via macrophage scavenger receptor charged domains. Bioconjug Chem (2012) 0.91
Clinically viable magnetic poly(lactide-co-glycolide) particles for MRI-based cell tracking. Magn Reson Med (2014) 0.90
Effect of nanoparticles on protein folding and fibrillogenesis. Int J Mol Sci (2009) 0.90
Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev (2009) 3.08
Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm (2008) 2.94
Nanotechnology safety concerns revisited. Toxicol Sci (2007) 2.41
Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. Nanomedicine (2008) 1.99
Characterization of nanoparticles for therapeutics. Nanomedicine (Lond) (2007) 1.62
Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory. Integr Biol (Camb) (2013) 1.30
Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 1.30
Rapid distribution of liposomal short-chain ceramide in vitro and in vivo. Drug Metab Dispos (2008) 1.24
Induction of autophagy in porcine kidney cells by quantum dots: a common cellular response to nanomaterials? Toxicol Sci (2008) 1.23
Fullerenol cytotoxicity in kidney cells is associated with cytoskeleton disruption, autophagic vacuole accumulation, and mitochondrial dysfunction. Toxicol Appl Pharmacol (2010) 1.20
Method for analysis of nanoparticle hemolytic properties in vitro. Nano Lett (2008) 1.20
Translational considerations for cancer nanomedicine. J Control Release (2010) 1.12
Lack of significant dermal penetration of titanium dioxide from sunscreen formulations containing nano- and submicron-size TiO2 particles. Toxicol Sci (2010) 1.11
Nanoparticle size and surface charge determine effects of PAMAM dendrimers on human platelets in vitro. Mol Pharm (2011) 1.01
Ambiguities in applying traditional Limulus amebocyte lysate tests to quantify endotoxin in nanoparticle formulations. Nanomedicine (Lond) (2010) 0.95
Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion. J Control Release (2013) 0.93
Activation of the MAP kinase cascade by exogenous calcium-sensing receptor. Mol Cell Endocrinol (2003) 0.89
Nanomedicines: addressing the scientific and regulatory gap. Ann N Y Acad Sci (2014) 0.88
Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. J Control Release (2013) 0.87
Dendrimer-induced leukocyte procoagulant activity depends on particle size and surface charge. Nanomedicine (Lond) (2011) 0.87
Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics. Expert Opin Drug Deliv (2015) 0.83
Choice of method for endotoxin detection depends on nanoformulation. Nanomedicine (Lond) (2013) 0.80
Synergistic combination therapy with nanoliposomal C6-ceramide and vinblastine is associated with autophagy dysfunction in hepatocarcinoma and colorectal cancer models. Cancer Lett (2013) 0.80
Inhibition of phosphoinositol 3 kinase contributes to nanoparticle-mediated exaggeration of endotoxin-induced leukocyte procoagulant activity. Nanomedicine (Lond) (2013) 0.80
Polymeric curcumin nanoparticle pharmacokinetics and metabolism in bile duct cannulated rats. Mol Pharm (2013) 0.79
Immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics. Expert Opin Biol Ther (2015) 0.78
Analysis of fullerene-based nanomaterial in serum matrix by CE. Electrophoresis (2007) 0.75
Quantitative analysis of PEG-functionalized colloidal gold nanoparticles using charged aerosol detection. Anal Bioanal Chem (2015) 0.75